VANCOUVER, June 4 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP), a medical technology company announces that it has received a Health
Canada license for a next-generation multi-purpose laser system that is
suitable for a broad range of applications in high volume settings, such as
hospitals and large institutions. This system will initially be directed
towards decolonization of potentially pathogenic bacteria such as S. aureus
and MRSA in the nose, as well as for the decolonization of microorganisms from
Photodisinfection utilizes photoactive agents and light sources to effect
potent, broad-spectrum disinfection across a variety of dental, medical and
other applications. The Company's photodisinfection laser is expected to
provide an alternative resource to antibiotics for clinicians and patients in
the eradication of S. aureus and resistant 'superbugs' including MRSA.
According to the Centers for Disease Control and Prevention (CDC), antibiotic
resistance has become 'one of the world's most pressing public health
"With rates of hospital-acquired infections and antibiotic resistance
rising steeply, it is imperative that non-antibiotic, anti-infective therapies
are developed," stated Carolyn Cross, Ondine's President and CEO. "Many
hundreds of clinicians in Canada and the European Union are successfully using
our Periowave(TM) photodisinfection technology for the treatment of
periodontal disease. We believe that this technology may be capable of
addressing many other clinically unmet needs where a broad-spectrum, safe,
non-antibiotic therapy is required. We intend to commercialize additional
applications of our versatile photodisinfection platform through strategic
partners, leveraging in-house expertise in rapid product development,
regulatory affairs and existing sales and marketing channels."
About MRSA and Antibiotic Resistance
The MRSA 'superbug' has become resistant to most antibiotics.
Approximately 95% of all patients with an MRSA infection do not respond to
first-line antibiotics. If the bacterium enters the bloodstream, nearly half
of these critically ill patients will die despite access to potent
antibiotics. Healthy people (including hospital healthcare workers) carry MRSA
bacteria in their noses and on the skin, and inadvertently pass it on to
others or self-infect by sneezing, breathing, or by touch-based transfer.
More than two million hospital-acquired infections occur each year in the
U.S. Antibiotic resistance is becoming a growing concern; it is crucial that
new non-antibiotic modalities to fight bacterial infections are developed.
Over the last decade, almost every class of bacteria has become less
responsive to antibiotics and the burden on the healthcare system related to
treating antibiotic resistant infections exceeds $8 billion in both the U.S.
and U.K. It is estimated that the annual cost associated with treating MRSA is
the U.S. is approximately US$4 billion.
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is based in Vancouver, British Columbia,
Canada, with a research laboratory in Bothell, Washington, and an
international office in St Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com.
Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
For further information:
For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
email@example.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, firstname.lastname@example.org; Canaccord
Adams Ltd, Nominated Adviser & Broker, Neil Johnson, Ryan Gaffney, +4420 7050